Trends of multidrug-resistant tuberculosis clustering in Portugal

Rita Macedo; Raquel Duarte

doi:10.1183/23120541.00151-2018

Tables

TABLE 1

Microbiological and demographic characteristics of the patients enrolled in the study

Lab no.	Diagnosis year	Exclusion reason	Sex	Age years	Region of isolation	MDR/XDR-TB	STR	INH	RMP	EMB	PZA	AMI	CAP	ETI	MOX	OFL	LIN	KAN	CIC	PAS	Cluster no.
S199228	2014		M	42	LTV	XDR	R	R	R	R	R	R	R	R	R	R	S	S	S	S
	2014	No culture isolation	M	43	LTV	XDR	R	R	R	R	R	R	R	R	R	R	S	S	S	S
	2014	Only LPA	M	47	LTV	MDR	NA	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
TB25429	2014		M	41	LTV	MDR	R	R	R	R	R	S	S	R	S	S	S	S	S	S	6
P1595	2014		M	37	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	1
P1279	2014		F	31	LTV	MDR	R	R	R	R	R	S	S	R	S	S	S	R	S	S
S207797	2014		M	53	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	2
P1428	2014		M	48	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	1
P1378	2014		M	50	LTV	XDR	R	R	R	R	R	S	S	R	R	R	S	R	S	S	3
P163	2014		M	53	LTV	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
TB24818	2014		F	32	LTV	MDR	R	R	R	R	S	S	S	S	S	S	S	S	S	S	7
P291	2014		M	28	LTV	MDR	R	R	R	R	S	S	S	S	S	S	S	S	S	S
TB25274	2014		M	37	LTV	XDR	R	R	R	R	R	S	S	R	S	R	S	R	R	S
S211891	2014		M	36	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S	7
P1599	2014		M	43	LTV	MDR	R	R	R	R	S	S	S	S	S	S	S	S	S	S	6
P187	2014		M	58	LTV	MDR	R	R	R	R	R	S	S	R	S	S	S	S	S	S	2
P88	2014		M	63	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S	4
P423	2014		F	75	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S	4
P292	2014		F	41	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S	4
P1536	2014		M	23	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S	4
P729	2014		M	47	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S
P356	2014		M	42	North	MDR	S	R	R	S	S	S	S	S	S	S	S	S	S	S
P92	2014		M	59	Centre	MDR	R	R	R	S	S	S	S	R	S	S	S	S	S	S	2
P340	2014		M	48	Centre	XDR	R	R	R	R	S	R	S	R	S	R	S	R	S	S	3
	2015	Only LPA	M	31	LTV	MDR	NA	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
P2624	2015		M	28	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S	7
P1928	2015		M	61	LTV	MDR	R	R	R	R	R	S	S	R	S	S	S	S	S	S	1
P1229	2015		M	39	LTV	XDR	R	R	R	R	R	R	R	R	R	R	S	R	S	S	1
P1876	2015		M	55	LTV	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
P1926	2015		M	52	LTV	XDR	R	R	R	R	R	R	R	R	R	R	S	R	S	S	1
P2829	2015		M	44	LTV	MDR	S	R	R	S	S	S	S	R	S	S	S	S	S	S	1
P2184	2015		M	75	LTV	MDR	R	R	R	R	R	R	R	R	S	S	S	R	S	S	1
P1994	2015		M	41	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	2
P2058	2015		M	57	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S
TB24737	2015		M	44	LTV	XDR	R	R	R	R	R	R	R	S	R	R	S	R	S	R
P1585	2015		F	42	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S	3
P2354	2015		F	27	LTV	MDR	R	R	R	R	R	R	R	S	S	S	S	R	S	S
P2471	2015		M	34	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S	3
	2015	Only LPA	F	32	LTV	MDR	NA	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
P884	2015		M	61	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	2
P2579	2015		M	35	LTV	MDR	R	R	R	R	R	S	S	R	S	S	S	S	S	S
P2452	2015		M	57	North	MDR	R	R	R	S	S	S	S	R	S	S	S	S	S	S	3
P982	2015		M	37	North	MDR	R	R	R	R	R	S	S	S	S	S	S	S	S	S
P1880	2015		M	58	North	MDR	R	R	R	S	S	S	S	S	S	S	S	R	S	S
P2353	2015		M	21	Island of Madeira	MDR	S	R	R	R	S	S	S	R	S	S	S	S	S	S	5
P27	2015		M	44	Algarve	MDR	S	R	R	S	S	S	S	R	S	S	S	S	S	S
	2015	Only LPA	M	39	Alentejo	MDR	NA	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
S308144	2016		M	41	LTV	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
S309968	2016		F	41	North	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S	4
S310368	2016		M	42	North	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
S312205	2016		F	63	LTV	MDR	S	R	R	S	R	R	R	R	S	S	S	R	S	S	1
S314371	2016		M	15	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S	6
S324134	2016		M	61	Centre	MDR	R	R	R	R	R	S	S	S	S	S	S	R	S	S
	2016	No culture isolation	F	45	LTV	MDR	R	R	R	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA
S326551	2016		M	40	LTV	MDR	R	R	R	R	R	S	S	S	S	S	S	S	S	S
S327889	2016		F	22	LTV	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
S320857	2016		M	43	LTV	MDR	R	R	R	R	R	S	S	S	S	S	S	S	S	S
S316569	2016		M	54	North	MDR	R	R	R	S	S	R	R	S	S	S	S	R	S	S
S326782	2016		M	62	North	MDR	R	R	R	S	S	S	S	R	S	S	S	S	S	S	3
S340248	2016		M	20	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	2
TB31393	2016		F	40	LTV	MDR	R	R	R	S	S	S	S	S	S	S	S	S	S	S
S332846	2016		M	70	Centre	MDR	R	R	R	S	R	S	S	S	S	S	S	S	S	S
S347401	2016		F	20	LTV	MDR	R	R	R	R	S	S	S	R	S	S	S	S	S	S
ACC	2016		F	40	LTV	MDR	R	R	R	S	R	S	S	R	S	S	S	S	S	S	2
S333605	2016		M	62	North	MDR	R	R	R	S	S	S	S	R	S	S	S	S	S	S	3
S348387	2016		M	UNK	Centre	MDR	S	R	R	S	S	S	S	S	S	S	S	S	S	S
S352139	2017		F	22	Centre	MDR	R	R	R	R	R	S	S	S	S	S	S	S	S	S	6
S375001	2017		F	22	Centre	MDR	S	R	R	R	S	S	S	R	S	S	S	S	S	S	5
S374686	2017		F	34	LTV	MDR	S	R	R	R	R	S	S	R	S	S	S	S	S	S
S381277	2017		M	30	North	MDR	R	R	R	R	S	S	S	S	S	S	S	S	S	S
TB33470	2017		M	52	LTV	MDR	S	R	R	R	R	S	S	R	S	S	S	S	S	S	1
S389865	2017		F	59	North	MDR	R	R	R	R	R	S	S	S	S	S	S	S	S	S
S387683	2017		M	56	LTV	XDR	R	R	R	R	R	R	S	R	R	R	S	R	S	S	3
S399045	2017		F	41	North	MDR	R	R	R	S	S	S	S	R	R	R	S	S	S	S
S396397	2017		M	51	LTV	XDR	R	R	R	R	R	R	R	R	S	S	S	R	S	S	1
S399986	2017		M	58	LTV	MDR	R	R	R	R	S	S	S	R	R	R	S	S	S	S	3
TB34192	2017		M	62	LTV	MDR	R	R	R	S	S	S	S	R	S	S	S	S	S	S	2
	2017	Only LPA	M	54	North	MDR	NA	R	R	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

MDR: multidrug-resistant; XDR: extensively drug-resistant; TB: tuberculosis; STR: streptomycin; INH: isoniazid; RMP: rifampicin; EMB: ethambutol; PZA: pyrazinamide; AMI: amikacin; CAP: capreomycin; ETI: ethionamide; MOX: moxifloxacin; OFL: ofloxacin; LIN: linezolid; KAN: kanamycin; CIC: cycloserine; PAS: para-aminosalicylic acid; M: male; F: female; LTV: Lisbon and Tagus Valley; R: resistant; S: sensitive; NA: not available; LPA: line-probe assay; UNK: unknown.